Awards + Funding
"We're proud to have been recognized as an industry leader in our field."
As an emerging biotechnology company, the innovative research of Affinity Therapeutics has already garnered numerous awards and accolades.
In 2012, we were awarded a $400,000 Phase I Small Business Innovative Research grant from the National Institutes of Health to further our development of an affinity-based microparticle delivery platform comparable to that of coated mesh. This delivery platform would provide sustained, extended delivery of antimicrobials to treat and prevent common bacterial pathogens that cause surgical site infections.
In 2013, we also were awarded a $150,000 Phase I Small Business Innovative Research grant by the National Science Foundation to further our research in the development of a drug delivery ring, comparable to other products currently used for contraception. Our product, however, would prevent person-to-person HIV transmission—a benefit not found in products on the market today. In addition to these, Affinity has many other research proposals being reviewed for funding by multiple agencies.
In 2014, we received another $400,000 SHIFT (Small Businesses Helping Investigators to Fuel the Translation of Scientific Discoveries) award from the National Institutes of Health. “This funding represents the hard work and dedication of the entire Affinity team and positions Affinity to become a serious player in the cardiovascular medical device space,” said Julius Korley, chief scientific officer and president.